Live Breaking News & Updates on Ellen Chiniara

Stay updated with breaking news from Ellen chiniara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $56.00 at Piper Sandler

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $56.00 at Piper Sandler
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Jeffreyw Albers , Ellen Chiniara , Stifel Nicolaus , Piper Sandler , Wolfe Research , Voloridge Investment Management , Group Plc , Pricet Rowe Associates Inc , Wells Fargo Company , Kymera Therapeutics Inc , Nuveen Asset Management , Vanguard Group Inc , Kymera Therapeutics , Get Free Report , Wells Fargo , Director Jeffrey , General Group Plc , Investment Management , Asset Management , Kymera Therapeutics Daily ,

Stifel Nicolaus Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $55.00

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective upped by Stifel Nicolaus from $35.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.84% from the stock’s previous close. Other research analysts […] ....

United States , Hong Kong , Piper Sandler , Ellen Chiniara , Stifel Nicolaus , Jeffreyw Albers , Stifel Nicolau , Royal Bank , Tower Research Capital , Kymera Therapeutics Inc , Morgan Stanley , Hong Kong Ltd , Jpmorgan Chase Co , Advisors Asset Management Inc , Kymera Therapeutics , Get Free Report , Director Jeffrey , Kong Ltd , Asset Management , Research Capital , Kymera Therapeutics Daily , Nasdaq Kymr , Boost Price Target ,

Kymera Therapeutics (NASDAQ:KYMR) Trading Down 1.9% After Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) traded down 1.9% during trading on Monday following insider selling activity. The stock traded as low as $36.22 and last traded at $36.49. 178,419 shares changed hands during trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at […] ....

Hong Kong , Piper Sandler , Jared Gollob , Ellen Chiniara , Kymera Therapeutics Inc , Morgan Stanley , Securities Exchange Commission , Royal Bank , Wells Fargo Company , Tower Research Capital , Advisors Asset Management Inc , Hong Kong Ltd , Jpmorgan Chase Co , Kymera Therapeutics , Get Free Report , Exchange Commission , Kong Ltd , Asset Management , Research Capital , Kymera Therapeutics Daily , Nasdaq Kymr ,

Leerink Partnrs Weighs in on Kymera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Kymera Therapeutics in a research report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.79) per share for the quarter. Leerink Partnrs currently has […] ....

Hong Kong , United States , Piper Sandler , Jeffreyw Albers , Leerink Partnrs , Ellen Chiniara , Tower Research Capital , Hong Kong Ltd , Royal Bank , Jpmorgan Chase Co , Kymera Therapeutics Inc , Morgan Stanley , Kymera Therapeutics Company Profile , Advisors Asset Management Inc , Kymera Therapeutics , Free Report , Kymera Therapeutic , Director Jeffrey , Kong Ltd , Asset Management , Research Capital , Get Free Report , Kymera Therapeutics Daily , Nasdaq Kymr , Earnings Estimates ,